The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Beginner’s guide to Inan-speak:
“Tag team drivel”
Any post(s) attempting to bring about clarity and accuracy, especially when they expose his own “erroneous posts”.
Tag Team Drivel ...
ATB
Bermuda,
Many thanks for the explanation. As always you bring accuracy and clarity to the board.
I think most of us long term holders get it but those not as well versed in the history may have been mislead.
his doctors did not agree with that ...........
he suggested ... ATB
Inanaco,
I haven't responded because I had made my point.
The whole article is about hyperprogression and the passages in your 9.52 and 9.59 concern a patient who believes his immunotherapy treatment turbocharged the growth of his tumour. You replied with the comment 'SCIB1 had that effect on one patient .... ' ................it didn't, in any sense. The only effect SCIB1 had on patient's tumours was to shrink them, never to cause them to grow. I now know that's not what you meant but it's what your post suggested.
Just for clarity and for the benefit of anybody new looking at Scancell or perhaps more importantly at SCIB1, one of the biggest advantages of SCIB1 is its excellent safety record. In clinical trials it has shown itself to be safe and well tolerated with no serious adverse events.
just to help you along Ruck
The thread Title
is that a question mark ........... ?
Immonotherapy worsens cancer ?
oh yea
already explained ...
Seems Bermuda has understood
Inan,
TF posts an article with a sensational title, within which it highlights a possible phenomenon “hypoprogression”.
In response to this you posted:
”SCIB1 had that effect on one patient .”
You can understand how this may perturb investors and potential patients. We are having enough problems recruiting patients for the SCIB1 trial as it is without this sort of scaremongering albeit unintentional. You really have to be more careful in your choice of words.
Perhaps you could clarify what you meant by the “that effect” SCIB1 had and what the source of your information is. In your own words rather than a cut and paste obfuscation.
CAR T-Cell Therapy for Lymphoma
CAR T-cell therapy is a promising treatment for some patients with aggressive non-Hodgkin lymphoma (NHL) that has not responded to other therapies (refractory). It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer. The FDA has approved two CAR T-cell therapies for lymphoma: Yescarta™ and Kymriah™. Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) is one of the first centers to make the FDA-approved therapies available as standard of care to patients who have not had effective treatment options.
Yescarta (also referred to as axicabtagene ciloleucel) is approved for aggressive, relapsed and/or refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. The clinical trials of Yescarta showed the therapy to be highly effective with 82 percent of patients responding to the CAR T-cell therapy, including 54 percent who had a complete response (i.e., no sign of cancer). The most recent follow-up data shows that at a median 15.4 months after treatment, 40 percent of patients remain in complete remission, showing the lasting effectiveness of this therapy.
Kymriah (also referred to as tisagenlecleucel) is approved for patients with relapsed or refractory (r/r) large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. In clinical trials, patients had strong responses from this therapy: 53 percent responded to treatment, with 40 percent achieving a complete response (i.e. no sign of cancer). Kymriah is also approved for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) up to age 25. Learn more about Kymriah for pediatric B-cell ALL.
let me think now ... does the press sensationalise an article ..
Maybe
so to explain ... ‘I asked my doctors, “Why is this happening to me?” They didn’t know.
in which case the same effect was seen in Scancells patient, it was not until they surgically removed the lesion did they discover this particular Met was in effect immune from the vaccine ...
so .... the Doctors did NOT describe the patient in the article ..as Hyperprogression ...
made be you can explain how you managed to do that ? as I did not
I think you should read the article ..
""But some doctors doubt that hyperprogression even exists, arguing that these patients would possibly have deteriorated rapidly, regardless of what treatment they had ""
‘I asked my doctors, “Why is this happening to me?” They didn’t know. I understand that my lymphoma was very aggressive from the start, but since having CAR-T, it’s just got so bad, so quickly. From where I’m sitting, it looks like the treatment made me worse.’
Of course, the cancer may have progressed this way, regardless of what treatment he had. But could he be right?
Inanaco,
What makes you say that SCIB1 caused hyperprogression, have you read it somewhere? The clinical trial report for SCIB1 simply says that the patient developed further lesions due to disease progression and hyperprogression was definitely not listed as an adverse event for any patients.
I don't remember ever reading anything that suggested SCIB1 can cause hyperprogression. It would be a concern if you are correct so it's important to clarify.
SCIB1 had that effect on one patient .... one particular Met developed which turned out to be immune from the vaccine, it was surgically removed ..
This is actually the beauty of moditope ... because its not targeting a mutation, its targeting a Cells tool box to survive which is what the immune system is designed to do ie .. look for stressed cells
you need to trust your CD4 T cells ....... Lindy does
That's the Mail's headline . . . CAR-T therapy under the cosh in the Daily Mail
"Last summer, Joseph McMullan learned that he would become one of the first British patients to receive CAR-T therapy – a breakthrough cancer treatment designed to turbo-charge the immune system to seek out and destroy tumour cells. He believed he’d been thrown a lifeline after chemotherapy failed. The treatment has, with some justification, been dubbed a game-changer, a miracle cure, and even ‘magic’: in trials, some patients with seemingly untreatable and aggressive illness had been brought back from the brink."
https://www.dailymail.co.uk/health/article-7902251/Doctors-fear-immunotherapy-actually-make-cancer-WORSE.html